Informations générales (source: ClinicalTrials.gov)
A Prospective, Randomized, Dual-arm Multi-center Study to Assess the Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA5 Device in Combination With a Stent Retriever (ATHENA)
Interventional
N/A
Anaconda Biomed S.L. (Voir sur ClinicalTrials)
septembre 2024
mars 2026
26 avril 2025
The objective of this study is to assess the safety and effectiveness of mechanical
thrombectomy using the ANA funnel catheter to treat people with acute ischemic stroke
within 24 hours of symptom onset. The device facilitates the placement of other devices
such as stent retrievers and intravascular catheters during the procedure.
Etablissements
Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
---|---|---|---|---|---|
HOPITAL FOCH | ARTURO CONSOLI | 05/05/2025 07:12:15 | Contacter |
Critères
Tous
Inclusion Criteria:
1. A new focal disabling neurologic deficit consistent with acute cerebral ischemia.
2. Baseline National Institutes of Health Stroke Scale (NIHSS) obtained prior to
procedure ≥ 8 points and ≤ 25 points.
3. Pre-ictal modified Rankin Score (mRS) score of 0,1 or 2.
4. Treatable within 24 hours of symptom onset, defined as point in time when the
subject was last observed to be asymptomatic; treatment start is defined by arterial
puncture time.
5. If indicated, thrombolytic therapy shall be initiated per the institution's usual
care and the most recent version of the AHA/ASA Guidelines. Subjects eligible for IV
thrombolysis should receive it without delay.
6. Occlusion (eTICI ≤ 1 flow) of the terminal carotid artery, middle cerebral artery M1
segment or, dominant or proximal M2 segment, indicated for mechanical thrombectomy,
confirmed with conventional angiography or CTA/MRA.
Key
1. A new focal disabling neurologic deficit consistent with acute cerebral ischemia.
2. Baseline National Institutes of Health Stroke Scale (NIHSS) obtained prior to
procedure ≥ 8 points and ≤ 25 points.
3. Pre-ictal modified Rankin Score (mRS) score of 0,1 or 2.
4. Treatable within 24 hours of symptom onset, defined as point in time when the
subject was last observed to be asymptomatic; treatment start is defined by arterial
puncture time.
5. If indicated, thrombolytic therapy shall be initiated per the institution's usual
care and the most recent version of the AHA/ASA Guidelines. Subjects eligible for IV
thrombolysis should receive it without delay.
6. Occlusion (eTICI ≤ 1 flow) of the terminal carotid artery, middle cerebral artery M1
segment or, dominant or proximal M2 segment, indicated for mechanical thrombectomy,
confirmed with conventional angiography or CTA/MRA.
Key
1. Subject was diagnosed with a stroke in the past year.
2. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.
3. Severe, sustained uncontrolled hypertension refractory to treatment (systolic blood
pressure >185 mmHg or diastolic blood pressure >110 mmHg).
4. Known pregnancy and/or lactating female.
5. CT or MRI evidence of hemorrhage (the presence of microbleeds is allowed).
6. Significant mass effect with midline shift.
7. Evidence of intracranial tumor (except small meningioma).
8. History of preexisting stent proximal to or at the occlusion site that may preclude
safe deployment or recovery of the stent retriever.
9. Vessel tortuosity too difficult to allow endovascular access of the intracranial ICA
per investigator judgement. Indicators of vessel tortuosity include but are not
limited to the presence of carotid loops and type 3 aortic arches.
10. Evidence of tandem lesions, including complete occlusion, high grade stenosis or
arterial dissection in the extracranial or internal carotid artery (ICA), requiring
treatment or preventing access to thrombus.
11. Subjects with known or suspected underlying intracranial atherosclerotic lesions
responsible for the target occlusion.
12. Subjects with occlusions in multiple vascular territories (e.g., bilateral anterior
circulation, or anterior/posterior circulation).
13. Anatomical or physiological restrictions (e.g., severe stenosis, vasospasm, high
tortuosity, etc.) detected via angiogram likely to result in an inability to
position the guide catheter or to deploy the ANA or intermediate catheter in the
targeted ICA segment with acceptable vessel diameter as defined in the Instructions
for Use.